Fluvoxamine for Acute COVID-19 Infection: Weak Hypothesis, Predictable Failure

Am J Ther. 2022 May-Jun;29(3):e342-e343. doi: 10.1097/MJT.0000000000001502. Epub 2022 Mar 29.

Author

Peter Manu¹

Affiliation

¹ Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.

PMID: 35383592
DOI: 10.1097/MJT.0000000000001502

No abstract available

Publication types

Editorial

MeSH terms

COVID-19 Drug Treatment*
Fluvoxamine / therapeutic use
Humans
SARS-CoV-2
Selective Serotonin Reuptake Inhibitors

Substances

Serotonin Uptake Inhibitors
Fluvoxamine